Comparison between Carbetocin and Oxytocin in preventing blood loss during Caesarean Section

Carbetocin versus Oxytocin for prevention of post partum haemorrhage during caesarean section : a single blind randomized controlled trial in a tertiary care centre - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/111044

Enrollment

220

Registered

2026-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O721- Other immediate postpartum hemorrhage

Interventions

Intervention1: Carbetocin: Single Intravenous Bolus of 100 mcg given slowly over one minute after delivery of the baby Control Intervention1: Oxytocin: Oxytocin infusion containing 10 IU per mL in 50

Eligibility

Inclusion criteria

Inclusion criteria: All consenting full term low risk pregnant women undergoing elective or emergency lscs

Exclusion criteria

Exclusion criteria: 1. Non Consenting Patients 2. Patients allergic to Oxytocin and/or Carbetocin 3. Patients with severe hepatic/ renal / cardiovascular disorders 4. Patients at greater risk for PPH ( patients with multifetal gestation, macrosomia, placenta praevia, preeclampsia, polyhydramnios, coagulation disorders )

Design outcomes

Primary

Measure	Time frame
Estimated blood loss during LSCS and 24 hours postpartum.Timepoint: Baseline Hb, Estimated blood loss during LSCS and 24 hrs after LSCS	—

Secondary

Measure	Time frame
To compare haemodynamic changes after administration of carbetocin and oxytocinTimepoint: baseline, one minute after intervention, five minutes after intervention, at the end of uterine closure, at the end of skin closure;To assess the need for additional uterotonic agents in both groupsTimepoint: during LSCS and Anytime within 24 hrs of LSCS;to compare the requirement of blood transfusion in the two groupsTimepoint: during LSCS and anytime Within 24 hrs of LSCS;to evaluate and compare maternal adverse effects associated with carbetocin and oxytocinTimepoint: during LSCS and Anytime within 24 hrs of LSCS;To assess the need for additional interventions for control of postpartum haemorrhageTimepoint: during LSCS and Anytime within 24 hrs of LSCS;to assess hb concentration after 24 hrs of LSCSin both groupsTimepoint: baseline and 24 hrs after LSCS	—

Measure

Time frame

To compare haemodynamic changes after administration of carbetocin and oxytocinTimepoint: baseline, one minute after intervention, five minutes after intervention, at the end of uterine closure, at the end of skin closure;To assess the need for additional uterotonic agents in both groupsTimepoint: during LSCS and Anytime within 24 hrs of LSCS;to compare the requirement of blood transfusion in the two groupsTimepoint: during LSCS and anytime Within 24 hrs of LSCS;to evaluate and compare maternal adverse effects associated with carbetocin and oxytocinTimepoint: during LSCS and Anytime within 24 hrs of LSCS;To assess the need for additional interventions for control of postpartum haemorrhageTimepoint: during LSCS and Anytime within 24 hrs of LSCS;to assess hb concentration after 24 hrs of LSCSin both groupsTimepoint: baseline and 24 hrs after LSCS

—

Countries

India

Contacts

Public ContactDr Aditi Katkar

Dr. Panjabrao Alias Bhausaheb Deshmukh Memorial Medical College

aditikatkarb81@gmail.com9890943385

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026